News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Achaogen Announces ACHN-490 Clinical Data at the 49th Annual ICAAC Meeting


9/14/2009 11:24:41 AM

SAN FRANCISCO--(BUSINESS WIRE)--Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, today announced the results of a Phase 1 trial and preclinical data on its lead drug candidate ACHN-490 at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting in San Francisco, CA. ACHN-490 has shown preclinical activity against multi-drug resistant (MDR) Gram-negative and Gram-positive pathogens, and is the most advanced drug in Achaogen’s next-generation aminoglycosides, or neoglycosides.

Read at BioSpace.com


comments powered by Disqus
Achaogen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES